Irm LLC

Novartis Ag

Greg Chopiuk

Nathanael Schiander Gray

Qiang Ding

Ruo W Steensma

Yi Liu

Qiong Zhang

Taebo Sim

Shuli You

Jiqing Jiang

Pingda Ren

Pascal Furet

Pamela Ann Albaugh

Donald Karanewsky

Yongqin Wan

Xing Wang

Guobao Zhang

Yongping Xie

Keiichi Masuya

Ichiro Umemura

Joseph Schoepfer

Carlos Garcia-Echeverria

Xia Wang

Takanori Kanazawa

Patricia Imbach

Osamu Ohmori

Naoko Matsuura

Takahiro Miyake

Eiji Kawahara

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, &#x3a3;&#x393;K, T&#x3b9;&#x3b5;2, &#x39b;&#x3c7;&#x3ba;, &#x3b8;NK2&#x3b1;2, MKK4, c-RAF, MKK6, SAPK2&#x3b1; and SAPK2&#x3b2; kinases.

Compounds and compositions as protein kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF&#x3b2;, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2&#x3b2; kinases.

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, EGF-R, c-erbB2 kinase (HER-2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF&#x3b2;, KDR, c-Kit, b-RAF, c-RAF, FLT1 and/or FLT4 kinases.

Methods and compositions as protein kinase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Greg Chopiuk